Should we be combining local tumor therapies with immunotherapies as standard? - Wikidata - wikimedia - TriplyDB

Should we be combining local tumor therapies with immunotherapies as standard?

Should we be combining local tumor therapies with immunotherapies as standard?

http://www.wikidata.org/entity/Q38638858

about

Should we be combining local tumor therapies with immunotherapies as standard?

http://www.wikidata.org/entity/Q38638858

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Should we be combining local tumor therapies with immunotherapies as standard?

@en

type

label

Should we be combining local tumor therapies with immunotherapies as standard?

@en

prefLabel

Should we be combining local tumor therapies with immunotherapies as standard?

@en

P1433

Q38638858-03519249-C604-4C8D-99FE-274BA1D05A92

P1476

Q38638858-E5B36BDF-ACE1-4900-8053-4D46BB14E56B

P2093

Q38638858-791F9A42-818B-471D-9826-C39328EC704D

Q38638858-F9A06F16-6004-4B8F-9038-A8063373B160

P2860

Q38638858-0439C7AF-F37B-42DE-95B1-68E5CE61D82F

Q38638858-3FEB0961-BFD5-4490-80B6-FB7680EAC0E1

Q38638858-4A63B86C-BFD5-41A7-906A-C000887B8E95

Q38638858-562CB4B6-E528-4486-80F6-5343EEB000C2

Q38638858-5BE98563-4DA1-47DF-9456-0283EFB73FEE

Q38638858-65688C27-3F89-4F71-AFE4-595AEF03C8C1

Q38638858-68C76A7C-9EC9-4CE3-AEDE-107B9CDA65FB

Q38638858-7F35B66E-B9B0-4DFD-BEE9-042FBA5D3008

Q38638858-864C3578-56E1-4865-A824-0E6A2181562C

Q38638858-8CFFC684-8C67-4C31-9F7C-7C9BC13B1D77

P304

Q38638858-BD796D11-FF87-421F-A27E-08D482FF07C6

P31

Q38638858-275F869B-319B-4F71-B0F7-190025EA0D83

Q38638858-f37ac5cb-0830-4cc5-a7bd-c64b0074f51c

P356

Q38638858-9D933716-669A-44EF-97D9-579D15E1C8ED

P407

Q38638858-A4BD899B-ADA6-401C-873B-89D25DFE1132

P433

Q38638858-CED91A2E-12C4-402D-8215-C7248CFB2EE9

P478

Q38638858-2952A520-C29C-4F55-9C71-50AB4EA08CEA

P50

Q38638858-248ABE53-B17C-4FC1-9816-A0B8FA63A8B1

Q38638858-F18D3A21-3D2E-4FC1-AA84-69C93A3B2542

P577

Q38638858-15EEA74D-DF75-4D22-BAFC-EDA678D167BB

P698

Q38638858-6CB23B8A-A0D7-4A35-8D19-E27D902BBD85

P356

P1433

Future Oncology

P1476

Should we be combining local tumor therapies with immunotherapies as standard?

@en

P2093

Christian Baues

http://www.w3.org/2001/XMLSchema#string

Max Schlaak

http://www.w3.org/2001/XMLSchema#string

P2860

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.

Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy.

Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.

A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.

Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.

P304

1573-1575

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2017-0150

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Michael von Bergwelt-Baildon

Sebastian Theurich

P577

2017-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28829189

http://www.w3.org/2001/XMLSchema#string